The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: A pooled analysis of literatures

Oncotarget

Volumn 7, Issue 12, 2016, Pages 15033-15046

  Lin, Ziying ^a,b,c   Xu, Yutong ^a,b,c   Zhang, Yaxiong ^a,b,c,d   He, Qihua ^a,b   Zhang, Jianrong ^a,b   He, Jianxing ^a,b   Liang, Wenhua ^a,b  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Cancer; Clinicopathological features; Meta analysis; Programmed death ligand 1

Indexed keywords

MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; TUMOR MARKER;

AGE DISTRIBUTION; ARTICLE; ASIAN; CAUCASIAN; CELL DIFFERENTIATION; CLINICAL FEATURE; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; LYMPH NODE METASTASIS; MALE; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; PREVALENCE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEX DIFFERENCE; SYNDROME DELINEATION; TUMOR DIFFERENTIATION; TUMOR VOLUME; CANCER STAGING; META ANALYSIS; METABOLISM; NEOPLASM; PATHOLOGY; PROGNOSIS;

B7-H1 ANTIGEN; BIOMARKERS, TUMOR; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS;

EID: 84962857991     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7590     Document Type: Article

References (43)

1. Greenwald RJ, Freeman GJ and Sharpe AH. The B7 family revisited. Annual review of immunology. 2005; 23:515-548.
2. Jin HT, Ahmed R and Okazaki T. Role of PD-1 in regulating T-cell immunity. Current topics in microbiology and immunology. 2011; 350:17-37.
3. Zha Y, Blank C and Gajewski TF. Negative regulation of T-cell function by PD-1. Critical reviews in immunology. 2004; 24:229-237.
4. D'Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, Tibaldi C, Minuti G, Salvini J, Coppi E, Chella A, Fontanini G, Filice ME, Tornillo L, Incensati RM, Sani S, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. British journal of cancer. 2015; 112:95-102.
5. Faraj SF, Munari E, Guner G, Taube J, Anders R, Hicks J, Meeker A, Schoenberg M, Bivalacqua T, Drake C and Netto GJ. Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma. Urology. 2015; 85:703.e701-706.
6. Yamane H, Isozaki H, Takeyama M, Ochi N, Kudo K, Honda Y, Yamagishi T, Kubo T, Kiura K and Takigawa N. Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. American journal of cancer research. 2015; 5:1553-1557.
7. Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T and Alix-Panabieres C. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol. 2015; 9:1773-1782.
8. Chang YL, Yang CY, Lin MW, Wu CT and Yang PC. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: A potential rationale for immunotherapy. Lung cancer. 2015; 88:254-259.
9. Topalian SL, Drake CG and Pardoll DM. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Current opinion in immunology. 2012; 24:207-212.
10. Flies DB, Sandler BJ, Sznol M and Chen L. Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy. The Yale journal of biology and medicine. 2011; 84:409-421.
11. Tsai KK, Zarzoso I and Daud AI. PD-1 and PD-L1 antibodies for melanoma. Human vaccines & immunotherapeutics. 2014; 10:3111-3116.
12. Brower V. Anti-PD-L1 antibody active in metastatic bladder cancer. The Lancet Oncology. 2015; 16:e11.
13. Gettinger S and Herbst RS. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. Cancer journal. 2014; 20:281-289.
14. Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S and Tortora G. PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises. Cancer treatment reviews. 2015; 41:114-121.
15. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y and Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in molecular medicine. 2015; 21:24-33.
16. Errico A. Immunotherapy: PD-1-PD-L1 axis: efficient checkpoint blockade against cancer. Nature reviews Clinical oncology. 2015; 12:63.
17. Patel SP and Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015; 14:847-856.
18. Carbognin L, Pilotto S, Milella M, Vaccaro V, Brunelli M, Calio A, Cuppone F, Sperduti I, Giannarelli D, Chilosi M, Bronte V, Scarpa A, Bria E and Tortora G. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. PloS one. 2015; 10:e0130142.
19. Postow MA, Callahan MK and Wolchok JD. Immune Checkpoint Blockade in Cancer Therapy. Journal of clinical oncology. 2015; 33:1974-1982.
20. Pauken KE and Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends in immunology. 2015; 36:265-276.
21. Sanmamed MF and Chen L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer journal. 2014; 20:256-261.
22. Ritprajak P and Azuma M. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. Oral oncology. 2015; 51:221-228.
23. Wasik MA, Zhang Q, Marzec M, Kasprzycka M, Wang HY and Liu X. Anaplastic lymphoma kinase (ALK)-induced malignancies: novel mechanisms of cell transformation and potential therapeutic approaches. Seminars in oncology. 2009; 36:S27-35.
24. Zhang Y, Zhang J, Xu K, Xiao Z, Sun J, Xu J, Wang J and Tang Q. PTEN/PI3K/mTOR/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer. Hepato-gastroenterology. 2013; 60:1766-1772.
25. Abildgaard C and Guldberg P. Molecular drivers of cellular metabolic reprogramming in melanoma. Trends in molecular medicine. 2015; 21:164-171.
26. Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism: clinical and experimental. 2015; 64:S16-21.
27. Milella M, Falcone I, Conciatori F, Cesta Incani U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S, Cognetti F and Ciuffreda L. PTEN: Multiple Functions in Human Malignant Tumors. Frontiers in oncology. 2015; 5:24.
28. Barbee MS, Ogunniyi A, Horvat TZ and Dang TO. Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology. The Annals of pharmacotherapy. 2015.
29. McDermott J and Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs of today (Barcelona, Spain : 1998). 2015; 51:7-20.
30. Gunturi A and McDermott DF. Nivolumab for the treatment of cancer. Expert opinion on investigational drugs. 2015; 24:253-260.
31. Jorgensen JT. Companion diagnostic assays for PD-1/PD-L1 checkpoint inhibitors in NSCLC. Expert review of molecular diagnostics. 2015:1-3.
32. Freeman-Keller M and Weber JS. Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Therapeutic advances in medical oncology. 2015; 7:12-21.
33. Marquez-Rodas I, Cerezuela P, Soria A, Berrocal A, Riso A, Gonzalez-Cao M and Martin-Algarra S. Immune checkpoint inhibitors: therapeutic advances in melanoma. Annals of translational medicine. 2015; 3:267.
34. Jia M, Feng W, Kang S, Zhang Y, Shen J, He J, Jiang L, Wang W, Guo Z, Peng G, Chen G, He J and Liang W. Evaluation of the efficacy and safety of anti-PD-1 and anti-PD-L1 antibody in the treatment of non-small cell lung cancer (NSCLC): a meta-analysis. Journal of thoracic disease. 2015; 7:455-461.
35. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515:563-567.
36. Popper HH, Ryska A, Timar J and Olszewski W. Molecular testing in lung cancer in the era of precision medicine. Translational lung cancer research. 2014; 3:291-300.
37. Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai T, Lydon C, Mach S, Avila AG, Wong JA, Rabin AR, et al. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunol Res. 2015; 3:855-863.
38. Wu P, Wu D, Li L, Chai Y and Huang J. PD-L1 and Survival in Solid Tumors: A Meta-Analysis. PloS one. 2015; 10:e0131403.
39. Abdel-Magid AF. Inhibitors of the PD-1/PD-L1 Pathway Can Mobilize the Immune System: An Innovative Potential Therapy for Cancer and Chronic Infections. ACS medicinal chemistry letters. 2015; 6:489-490.
40. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, Xu H, Nayar SK, Wang TS, Sidransky D, Anders RA, Topalian SL and Taube JM. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer immunology research. 2013; 1:54-63.
41. Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y, Chang XJ, Lu YY, Bai WL, Qu JH, Wang CP, Wang H, Lou M, Wang FS, Lv JY and Yang YP. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PloS one. 2011; 6:e23621.
42. Lyford-Pike S, Peng S, Young GD, Taube JM, Westra WH, Akpeng B, Bruno TC, Richmon JD, Wang H, Bishop JA, Chen L, Drake CG, Topalian SL, Pardoll DM and Pai SI. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer research. 2013; 73:1733-1741.
43. Fang W, Zhang J, Hong S, Zhan J, Chen N, Qin T, Tang Y, Zhang Y, Kang S, Zhou T, Wu X, Liang W, Hu Z, Ma Y, Zhao Y, Tian Y, et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. Oncotarget. 2014; 5:12189-12202. doi: 10.18632/oncotarget.2608.